109O - Health-related quality of life (QoL) after prophylactic cranial irradiation (PCI) vs no PCI for stage III NSCLC patients: Results from the NVALT-11...

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session ESMO-IASLC Best Abstracts
Topics Lung and other Thoracic Tumours
Palliative and Supportive Care
Surgery and/or Radiotherapy of Cancer
Presenter Willem Witlox
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors W. Witlox1, B. Ramaekers2, H. Groen3, A.C. Dingemans4, J. Praag5, J. Belderbos6, V. Van Der Noort7, H. Van Tinteren7, M. Joore1, D. De Ruysscher8
  • 1Clinical Epidemiology And Medical Technology Assessment, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 2Clinical Epidemiology And Medical Technology Assessment, Maastricht University Medical Center (MUMC), Maastricht/NL
  • 3Department Of Pulmonary Diseases, University Hospital Groningen (UMCG), 9700 RB - Groningen/NL
  • 4Department Of Pulmonology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 5Department Of Radiation Oncology, Erasmus University Medical Center, Rotterdam/NL
  • 6Department Of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 7Department Of Biometrics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 8Radiation Oncology (maastro Clinic), Maastricht University Medical Centre (MUMC)-MAASTRO clinic, 6229 ET - Maastricht/NL

Abstract

The NVALT-11/DLCRG-02 randomized phase III study compared PCI to observation after chemo-radiotherapy for stage III NSCLC and showed a significant decrease in time to develop symptomatic brain metastases in the PCI arm at the expense of more low-grade mostly neurological toxicity (HR 0.25 95% CI 0.11–0.58). We here report on the QoL.